Celcuity Inc. Announces Upcoming Financial Results Release
Celcuity Inc. (NASDAQ: CELC), a pioneering biotechnology company focused on innovative oncology therapies, has exciting news. The company will be releasing its financial results for the third quarter of 2025 after the market closes. This significant event is scheduled for a Wednesday, with management set to provide insights and updates during a webcast and teleconference.
Details on Conference Call and Webcast
The teleconference aims to engage both domestic and international investors, featuring a toll-free number for U.S. callers at 1-800-717-1738, while international participants can dial 1-646-307-1865. Additionally, a live webcast will allow participants to follow along with the presentation. Access to the webcast can be easily found online, ensuring that everyone has a chance to engage with the company's updates.
Post-Event Replay
For those unable to attend the live session, a replay of the webcast will be available on the Celcuity official website. This ensures that all stakeholders have an opportunity to review the key points discussed and gain insights on the company’s performance and future directions.
Understanding Celcuity's Vision
Celcuity is dedicated to advancing targeted therapies specifically designed for various solid tumor types. One of their prominent candidates is gedatolisib, a potent dual inhibitor targeting both the PI3K and mTOR pathways. This innovative approach differentiates gedatolisib from other therapies focused on these pathways, promising a comprehensive blockade that could significantly impact patient outcomes.
Current Clinical Trials
Celcuity's commitment to innovation is showcased through its clinical trials. The company's Phase 3 trial, known as VIKTORIA-1, has made remarkable progress. It is studying the effects of gedatolisib combined with fulvestrant, giving attention to patients with HR+/HER2- advanced breast cancer. Recently, this trial completed enrollment for its PIK3CA Wild-Type cohort and is also concluding enrollment for the PIK3CA mutant group.
Furthermore, Celcuity is pursuing groundbreaking research in a second Phase 3 trial, referred to as VIKTORIA-2. This study investigates the combination of gedatolisib with a CDK4/6 inhibitor and fulvestrant, seeking to provide first-line treatment alternatives for similar patient groups. In addition, they are conducting a Phase 1/2 trial focusing on patients with metastatic castration-resistant prostate cancer, expanding the therapeutic potential of gedatolisib.
The Future of Celcuity
As Celcuity continues to advance in its clinical trials, the company remains dedicated to reporting its findings and progress as they work to enhance patient care. Investors and interested parties are encouraged to stay updated and engaged with the company to follow their journey in the realm of oncology.
Frequently Asked Questions
What are the key details of the Celcuity financial results release?
Celcuity's financial results for Q3 2025 will be released after market close, with a teleconference and webcast scheduled for the same day to discuss the outcomes.
How can I participate in the conference call?
To participate, domestic callers can dial 1-800-717-1738, while international callers should use 1-646-307-1865 for access to the teleconference.
Where can I find the results after the call?
A replay of the call and the details discussed during the webcast will be available on Celcuity's website following the live event.
What is gedatolisib?
Gedatolisib is Celcuity's leading therapeutic candidate, designed to target and inhibit the PI3K and mTOR pathways, representing a novel approach in cancer therapy.
What trials are currently active at Celcuity?
Celcuity is currently involved in multiple clinical trials, including VIKTORIA-1 and VIKTORIA-2, both focused on assessing the efficacy of gedatolisib in various patient populations.
